Docetaxel is the first-line chemotherapy and the only approved chemotherapy for men with metastatic castrate resistant prostate cancer (CRPC). We all know that Docetaxel will stop working, so what do you do when this happens?
The Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY conducted a retrospective, bi-institutional review of Carboplatin and paclitaxel when used in men with CRPC who have failed docetaxel. Carboplatin and paclitaxel have demonstrated activity in CRPC, but published data are limited regarding use of these drugs after docetaxel failure.
The researchers looked at tolerability, response, and survival. Endpoints used modified Prostate Cancer Working Group 2 criteria (greater than or equal to 30% PSA decline within 3 months).
Twenty-five patients were identified from February 2000 to March 2008. Median pretreatment PSA was 130.2 ng/ml